uploads/2018/03/Chart-006-4-1.jpg

These Pfizer Products Saw Declining Sales in 4Q17

By

Updated

Products with declining sales in 4Q17

A few products in Pfizer’s (PFE) portfolio, including BMP2, Enbrel, EpiPen, Inylta, Norvasc, Lyrica EH, Viagra IH, Vfend, Zyvox, Pristiq, and Revatio, reported declining sales in 4Q17 following their loss of market share to the competition.

The above chart shows Pfizer’s revenues from products that have reported falls in their sales since 1Q16.

Article continues below advertisement

Negative growth products

Pfizer’s 4Q17 revenue was affected by lower sales of the following drugs:

  • BeneFIX’s revenue fell 11% to $150 million in 4Q17 driven by a 10% fall in international sales to $88 million and a 13% fall in US sales to $62 million.
  • Pfizer’s blockbuster drug Enbrel reported a 10% revenue fall to $634 million in 4Q17. This revenue included sales from outside the US and Canadian markets.
  • EpiPen, Mylan’s (MYL) blockbuster drug, contains a drug manufactured by Pfizer. Pfizer reported a 57% fall in revenue for the EpiPen to $37 million driven by lower sales both in US markets and outside US markets.
  • Inylta, an oncology drug, reported a 14% fall in revenue to $83 million in 4Q17 driven by a 14% fall in US sales to $31 million and a 14% fall in international sales to $52 million.
  • Viagra reported a 45% fall in revenue to $209 million in 4Q17 driven by a 63% fall in US sales to $102 million and substantially offset by a 1% rise in international sales to $107 million.
  • Zyvox reported a 29% fall in revenue to $61 million in 4Q17 driven by an 11% fall in international sales to $71 million.

The SPDR S&P Pharmaceuticals ETF (XPH) has 4.4% of its total holdings in Pfizer, 4.4% in Perrigo (PRGO), 4.3% in Merck & Co. (MRK), and 4.6% in Bristol-Myers Squibb (BMY).

Advertisement

More From Market Realist